Expect continued downward pressure on VRAX as the company sells shares into the market via the ATM. Monitor trading volume and any subsequent filings for actual share sales. The ATM allows continuous selling, which could cap any upside.
Price Chart
Executive Summary
Virax Biolabs filed a sticker prospectus supplement to increase the maximum aggregate offering amount under its existing At-The-Market (ATM) agreement with H.C. Wainwright to up to $2,070,060.20, on top of $3,658,152 already sold. This signals ongoing capital needs and potential dilution, as the new offering amount is roughly equal to the company's current $2M market cap.
Key Facts
- Maximum aggregate offering amount increased to $2,070,060.20 under the existing ATM agreement with H.C. Wainwright.
- Company previously sold $3,658,152 of ordinary shares under the same agreement.
- Authorized share capital is $12,500,000 divided into 500,000,000 ordinary shares of $0.025 par value each.
- As of August 27, 2026, total issued shares were 1,344,988 ordinary shares.
- Market capitalization is approximately $2M, making the new offering amount highly dilutive.
Financial Impact
Up to $2.07M in new equity issuance, representing ~100% of current market cap, leading to significant dilution for existing shareholders.
Risk Factors
- Substantial dilution from ongoing ATM sales.
- Potential stock price decline as new shares are issued.
- Continued cash burn without clear revenue catalyst.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-383683 |
| Document: 6-k_atm_sticker_suppleme.htm | 0001193125-26-383683 |
| Document: 0001193125-26-383683-index-headers.html | 0001193125-26-383683 |
| Document: 0001193125-26-383683-index.html | 0001193125-26-383683 |
| Document: 0001193125-26-383683.txt | 0001193125-26-383683 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 16d ago | 6-K | $1.85 | awaiting T+20 | — | $1.23 (−33.51%) |
Sep 4, 2026 7w ago | 6-K | $2.63 $2.03 | ▲ +22.81% | ▲ +24.53% | $1.23 (+53.23%) |
Sep 4, 2026 7w ago | EFFECT | $2.63 $2.40 | ▼ −8.57% | ▼ −9.17% | $1.23 (−53.14%) |
Aug 18, 2026 9w ago | 6-K | $2.76 $2.45 | ▼ −11.20% | ▼ −10.21% | $1.23 (−55.43%) |
Jul 31, 2026 12w ago | 6-K | $2.62 $2.82 | ▼ −7.63% | ▼ −4.65% | $1.23 (+53.05%) |
Jul 16, 2026 14w ago | 6-K | $3.90 $2.82 | ▼ −27.69% | ▼ −31.31% | $1.23 (−68.46%) |
Jul 9, 2026 15w ago | Press Release | $6.36 $2.77 | ▲ +56.45% | ▲ +58.69% | $1.23 (+80.66%) |
Jul 9, 2026 15w ago | 6-K | $6.36 $2.77 | ▼ −56.45% | ▼ −58.69% | $1.23 (−80.66%) |
Jun 24, 2026 17w ago | 6-K | $0.1350 $0.1276 | ▼ −5.48% | ▼ −6.11% | $1.23 (+811.11%) |
Jun 12, 2026 19w ago | 6-K | $0.1840 $0.1496 | ▼ −18.70% | ▼ −20.05% | $1.23 (+568.48%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers